The purpose of this study was to quantify the impact of baseline renal dysfunction on incidence and occurrence of cardiac arrhythmias in the coronary ICU.
In studies that discriminate between patients with normal and impaired renal function before start of colistin treatment, the incidence of nephrotoxicity was 2.5- to 7-fold higher in patients with baseline renal dysfunction [2, 5, 7].
Patients with acute coronary syndrome (ACS) and/or baseline renal dysfunction, as well as those undergoing percutaneous coronary intervention (PCI), are at particularly high risk of CIN, which, when occurring, may be followed by persistent worsening of renal function [ 2, 3].
Subjects with IDDM had significantly greater incidence of baseline renal dysfunction.
Among them, a patient had baseline renal dysfunction with a creatinine clearance of 21 ml/min, thus the treatment doses were adjusted in line with published recommendations.
Results of several clinical studies addressing baseline renal dysfunction have shown strong effects on the performance of new AKI biomarkers [ 13, 14].
First, the impact of worsening renal function (WRF) was recently questioned and data from the ESCAPE trial [ 4], as well as other recent studies, revealed that baseline renal dysfunction but not WRF is related to poor outcome.
In studies that discriminate between patients with normal and impaired renal function before start of colistin treatment, the incidence of nephrotoxicity was 2.5- to 7-fold higher in patients with baseline renal dysfunction [ 2, 5, 7].
The patients were divided into four groups to clarify the impact of baseline renal dysfunction as follows: CKDAKI (n = 54), CKDAKI (n = 20), CKDAKI (n = 39), and CKDAKI (n = 33).
Although we observed higher BP in those with baseline renal dysfunction (Table 1), BP measured at each visit did not predict renal dysfunction in GEE longitudinal analysis (Table 2).
